INTRODUCTION {#s1}
============

Intestinal neuronal dysplasia (IND) is a common congenital malformation of the enteric nervous system (ENS) ([@R1],[@R2]). It was first reported by Meier-Ruge in 1971 as a malformation of the enteric plexus in children who presented with clinical symptoms resembling Hirschsprung disease (HD). In 1983, Fadda et al. ([@R3]) proposed the classification of 2 clinically and histologically distinct subtypes of IND. Type A IND (IND-A), accounting for less than 5% of the cases observed, presents in the neonatal period and is due to delayed maturation of neuronal cells. Type B IND (IND-B) is a permanent illness with hyperganglionosis and giant ganglia of the submucosal and myenteric plexus and with symptoms of constipation and abdominal bloating. Because it comprises over 95% of all IND cases ([@R4]--[@R6]), many authors have considered IND almost as a synonym for IND-B ([@R7]).

Because of the overlap between the symptoms and signs of HD and IND, misdiagnosis often occurs in the initial diagnosis. Unfortunately, there is still no uniform diagnostic standard for IND. The current diagnostic criteria have been gradually revised by the Meier-Ruge et al. ([@R8]), and the disease concepts have changed over time. Muto et al. ([@R9]) have recently established the Japanese clinical practice guidelines for diagnosis, which were developed using the methodologies in the Medical Information Network Distribution System and a unique systematic review approach for the evaluation of small numbers of cases. Wu et al. ([@R10]) presented a novel diagnostic scoring system that was able to differentiate HD from IND by the area under the receiver operating characteristic (ROC) curve, which combines the 3 risk factors (meconium, age \<3 years, and male sex) and the results of the barium enema radiography, anorectal manometry, and acetylcholinesterase reaction tests. Among all mentioned diagnostic systems, the histological evaluation of colon tissue is considered as the gold standard for assessing the size of enteric ganglia and the proportion of immature neurons ([@R11]). However, the collection of a full-thickness colonic biopsy requires general anesthesia and suturing. Thus, to a large extent, patients are unwilling to accept the procedure. Moreover, IND diagnosis is complex and subjective and requires experienced pathologists. Therefore, a noninvasive and objective method for IND diagnosis is strongly needed.

DNA methylation has been found to be relevant for various human diseases such as neurodevelopmental, neurodegenerative, and psychiatric disorders and is a well-recognized biomarker ([@R12]). DNA methylation plays an important role in the proliferation, migration, and differentiation of neural crest stem cells, which are all involved in the development of the ENS. DNA methylation occurs in the promoters of all the transcription factors that are associated with ENS development, such as *DNMT3B, Sox10, EDNRB, PAX6, PAX7, NGFR,* and *NEUROD1* ([@R13]--[@R19]). Sox10, in particular, has been considered to be critical for neural progenitor differentiation during ENS development ([@R20]). It is first expressed in neural crest cells, including cells of vagal origin, as they delaminate from the neural tube, reflecting its crucial role in the development of these cells and of the ENS in particular ([@R21],[@R22]). However, whether *Sox10* promoter methylation in the peripheral blood can be used for the diagnosis of IND remains unclear. In this study, we performed *Sox10* promoter methylation sequencing in the peripheral blood of patients with HD and IND to determine whether this event could be associated with ENS anomalies and could therefore be exploited to develop a noninvasive method for IND diagnosis.

PATIENTS AND METHODS {#s2}
====================

Sample collection {#s2-1}
-----------------

This study was approved by the ethics committee of China Medical University. The colon specimens and paired blood samples were collected at the Department of Pediatric Surgery in Shengjing Hospital of China Medical University, Capital Institute of Pediatrics of Capital Medical University, and Harbin Children\'s Hospital from 2016 to 2018. Detailed information on the patients, including age, sex, clinical symptoms, and diagnosis, was retrieved. The subject cohort included 60 controls, 60 HDs, and 32 INDs. The control subjects were children without constipation and consisted of 21 colon/blood sample pairs from colonic trauma/colostomy patients (used in all the following analyses) and blood samples from 39 patients with inguinal hernia or superficial hemangioma but no gastrointestinal diseases. The latter blood samples were only used in the analysis of the area under the curve (AUC) in the ROC curve and to evaluate the diagnostic efficacy of blood *Sox10* promoter methylation. Diagnosis of IND-B and HD was made by 3 blinded pathologists, according to the most recent diagnostic criteria ([@R7]). Blood/colon sample pairs were collected from all patients with HD and IND. All the fresh samples were immediately stored in a −80 °C freezer.

Immunohistochemistry {#s2-2}
--------------------

Sections were incubated overnight at 4 °C with murine Sox10 primary antibody (1:100 dilution; Santa Cruz Biotechnology, Santa Cruz, CA) and then incubated for 45 minutes at room temperature. Samples were incubated with Biotin-conjugated rabbit anti-mouse secondary antibody (1:200 dilution; Santa Cruz Biotechnology) for 20 minutes and then incubated with streptomycin-biotin-peroxidase solution for 20 minutes. A DAB kit was used for staining, and sections were counterstained with hematoxylin. The sections were dehydrated by gradient alcohol and rehydrated with xylene. Sections were examined under a microscope, and the density of the positively stained area was calculated at a ×400 magnification. The total number of glial cells in 5 light microscopy fields was counted.

Western blot {#s2-3}
------------

Protein extracts were heated to 100 °C for 6 minutes and size fractionated. After blocking with 5% fat-free milk in Tris-buffered saline (1.5 hours, room temperature), extracts were incubated with mouse anti-Sox10 (58 kDa; 1:200 dilution; Santa Cruz Biotechnology) or anti-glyceraldehyde-3-phosphate dehydrogenase (36 kDa; 1:4,000 dilution; ImmunoWay Biotechnology Company, Plano, TX) at 4 °C overnight. Protein bands were detected using a chemiluminescent substrate kit (Pierce, Rockford, IL), and GAPDH served as a control.

Real-time PCR {#s2-4}
-------------

Total RNA was reverse transcribed into complementary DNA (cDNA; PrimeScript RT Reagent Kit with DNA Eraser, Takara Biotechnology, Shiga, Japan). Quantitative real time polymerase chain reaction (qRT-PCR) was performed using SYBR Premix Ex Taq (Takara Biotechnology, Shiga, Japan) on a 7500HT Fast Real-time PCR system (Applied Biosystems, Foster City, CA) as per the manufacturer\'s instructions. The qRT-PCR primers were as follows: Sox10F, 5′-CATCCAGGCCCACTACAAG-3′; Sox10R, 5′-AACTTCAGTTTCCCCATCTCG-3′; β-actinF, 5′-ACTCTTC CAGCCTTCCTTCC-3′; β-actinR, 5′-CGTCATACTCCTGCTTGCTG-3″.

Bisulfite genomic sequencing {#s2-5}
----------------------------

The 24 CpG sites in the *Sox10* gene fragment were analyzed (Figure [1](#F1){ref-type="fig"}). The DNA methylation levels were measured with an enzyme-linked immunosorbent assay--based commercial kit (MDQ1, Imprint Methylated DNA Quantification Kit, Sigma-Aldrich, St. Louis, MO). Specifically, 2 μg of DNA was diluted in the appropriate volume of lysis and binding buffers and incubated in a water bath at 42 °C for 30 minutes. PCR was performed using a Verity 96-well PCR reaction amplification instrument (ABI, Shanghai, China) under the following conditions: 98 °C for 4 minutes, 94 °C for 45 seconds, 66 °C for 45 seconds, 72 °C for 1 minute, 94 °C for 45 seconds, 56 °C for 45 seconds, 72 °C for 1 minute, 72 °C for 8 minutes, and 20 cycles under 94 °C. PCR products were examined by electrophoresis in 3% agarose. The purified PCR products were cloned and sequenced. SeqMan software 8.1 (Shanghai, China) was used to analyze the methylation level.

![The frame is the location of the primer, and the middle is the sequence to be tested. The Sox10 gene fragment contains 24 CpG sites, which are indicated above in the following order: 5, 9, 19, 32, 47, 54, 57, 68, 75, 96, 107, 111, 123, 127, 131, 179, 194, 225, 261, 282, 285, 294, 297, and 335.](ct9-10-e00093-g001){#F1}

Statistical analysis {#s2-6}
--------------------

Statistical analyses were performed using SPSS software version 13.0 (IBM, Armonk, NY). Continuous variables were expressed as medians with interquartile ranges (P25--P75), and *P* ≤ 0.05 was considered statistically significant. The ROC curve was constructed, and the maximal AUC was calculated to assess the optimal cutoff values of *Sox10* methylation to diagnose IND and to discriminate it from HD. The cutoff values for 100% of specificity and the 100% of positive predictive value (PPV) were also determined. Both of these 2 optimal cutoff values were declared before the start of the study.

RESULTS {#s3}
=======

Methylation level of the *Sox10* promoter gene in IND {#s3-1}
-----------------------------------------------------

Methylation-sensitive PCR was applied to analyze the status of *Sox10* promoter methylation in the peripheral blood of normal controls, patients with HD, and patients with IND at 24 CpG sites (Figure [2](#F2){ref-type="fig"}). In result, the 32nd locus of the *Sox10* promoter was the only site exhibiting differential methylation between the control and patient groups. At this locus, the blood level of methylation of the *Sox10* promoter was 100% (90%--100%; 95% confidence interval \[CI\], 92.29%--96.37%) in the control, 90% (80%--90%; 95% CI, 82.84%--87.83%) in HD, and 60% (50%--80%; 95% CI, 57.12%--69.76%) in IND (Figure [2](#F2){ref-type="fig"}a, b, e). In the colonic tissues, the 32nd locus of the *Sox10* promoter was completely methylated in controls (80%; range, 80%--90%; 95% CI, 80.77%--89.70%), moderately methylated in patients with HD (80%; range, 80%--90%; 95% CI, 79.58%--84.09%), and hypomethylated in patients with IND (60%; range, 50%--70%; 95% CI, 56.50%--67.24%; Figure [2](#F2){ref-type="fig"}b, d, f).

![Promoter methylation level of the Sox10 gene in IND. In the peripheral blood, the promoter methylation level at the 32nd locus of the Sox10 promoter was (**a**) 100% (90%--100%) in the control, (**c**) 90% (80%--90%) in HD, and (**e**) 60% (50%--80%) in IND. In colon specimens, the 32nd locus of the Sox10 gene promoter was (**b**) completely methylated in the control (80%; range, 80%--90%), (**d**) moderately methylated in the aganglionic segment in HD (80%; range, 80%--90%), and (**f**) hypomethylated in IND (60%; range, 50%--70%). HD, Hirschsprung disease; IND, intestinal neuronal dysplasia.](ct9-10-e00093-g002){#F2}

Expression of *Sox10* in the ENS {#s3-2}
--------------------------------

### Immunohistochemistry {#s3-2-1}

To address the expression pattern of Sox10 in the ENS, immunohistochemical staining was performed, and the result revealed that in the control group, Sox10 was mainly expressed in glial cells and in a few enteric neurons; the nerve plexus and cell morphology were homogeneous (Figure [3](#F3){ref-type="fig"}A,a). The number of glial cells and the plexus showed high proliferation in patients with IND (Figure [3](#F3){ref-type="fig"}B,b), and they moderately proliferated in the aganglionic segment of patients with HD (Figure [3](#F3){ref-type="fig"}C,c). The number of glial cells was 1.52 ± 0.98/cm^2^ in the control group, 4.27 ± 1.26/cm^2^ in the aganglionic segment of the HD group, and 7.54 ± 2.41/cm^2^ in the IND group.

![Immunohistochemical staining of Sox10 in the enteric nervous system. **A** and **a** are the control group: Sox10 was mostly expressed in glial cells and a few enteric neurons; the nerve plexus and cell morphology were homogeneous. **B** and **b** are the intestinal neuronal dysplasia group. The number of glial cells and the area of the nerve plexus markedly proliferated. There were more glial cells than in the control group and giant ganglia in the plexus with more than 8 nerve cells. **C** and **c** are the aganglionic segment of HD. No reactivity was seen in ganglia stained with Sox10, but more positively stained nerve fibers and glial cells were observed than the control (**A**--**C**: ×200, **a**--**c**: ×400). HD, Hirschsprung disease.](ct9-10-e00093-g003){#F3}

### Western blot {#s3-2-2}

The level of Sox10 expression was quantified by Western blot, and it was demonstrated lower in the normal colon than in the aganglionic segment of patients with HD and IND. The difference was statistically significant (*P* \< 0.05). The difference in *Sox10* expression between the controls and the patients with HD was not statistically significant (*P* \> 0.05) (Figure [4](#F4){ref-type="fig"}).

![Western blot analysis of Sox10 protein in the colon. (**a**) Electrophoresis of Sox10 protein in the colon. Lane 1 = aganglionic segment of HD, lane 2 = IND, lane 3 = ganglionic segment of HD, and lane 4 = normal colon. (**b**) Expression level analysis of Sox10 protein. \*Compared with the normal group, *P* \< 0.05, \#compared with IND, *P* \< 0.05. AS-HD, aganglionic segment of HD; GS-HD, ganglionic segment of HD; HD, Hirschsprung disease; IND, intestinal neuronal dysplasia.](ct9-10-e00093-g004){#F4}

### *Messenger RNA* expression {#s3-2-3}

The *Sox10* messenger RNA expression level was quantified by qRT-PCR; it was highest in patients with IND, moderate in patients with HD, and lowest in normal controls; qRT-PCR results were consistent with those of Western blot analysis.

### Blood *Sox10* promoter methylation correlates with *Sox10* expression levels in the colon {#s3-2-4}

To address the relationship between the level of *Sox10* promoter methylation in the blood and in the colon, blood and colon promoter methylation levels were correlated with the levels of Sox10 expression in paired blood and colon samples of 21 controls, 60 patients with HD, and 32 patients with IND. A negative correlation between the blood level of Sox10 promoter methylation at the 32nd locus and Sox10 expression level was noted in all groups (r = −0.89, Figure [5](#F5){ref-type="fig"}a). The levels of *Sox10* promoter methylation at the 32nd locus in the blood and the colon were positively correlated (r = 0.84, Figure [5](#F5){ref-type="fig"}b), and colonic *Sox10* promoter methylation was negatively correlated with *Sox10* expression in the colon (r = −0.83, Figure [5](#F5){ref-type="fig"}c).

![Correlation analysis between the Sox10 promoter methylation level in the peripheral blood and the Sox10 expression level in the colon. (**a**) Correlation analysis between the Sox10 promoter methylation in the blood and its expression level in the colon (r = −0.89). (**b**) Correlation analysis between the levels of Sox10 promoter methylation in the peripheral blood and the colon (r = 0.84). (**c**) Correlation analysis between the *Sox10* promoter methylation and its expression level in the colon (r = −0.83). The red lines are the correlation lines. HD, Hirschsprung disease; IND, intestinal neuronal dysplasia.](ct9-10-e00093-g005){#F5}

### Efficacy of *Sox10* promoter methylation in the blood in the diagnosis of IND {#s3-2-5}

To investigate the efficacy of blood *Sox10* promoter methylation in the diagnosis of IND and HD, we firstly expanded the control group from 21 to 60 cases to improve the confidence level and then calculated the AUC of the ROC curve. The AUC for the level of *Sox10* promoter methylation in the diagnosis of HD was 0.776 (95% CI, 0.692--0.859; *P* = 0.000; Figure [6](#F6){ref-type="fig"}a). The cutoff value of blood *Sox10* promoter methylation was determined to be 85% for HD, with a sensitivity of 46.7% and a specificity of 95.0%; the negative predictive value was 64.06%, and the PPV was 90.33%. However, with a cutoff of 95%, the sensitivity and specificity were 83.3% and 53.3%, respectively. Thus, *Sox10* promoter methylation was not suitable for HD diagnosis because of low efficacy.

![Diagnostic efficacy of blood Sox10 promoter methylation in IND. (**a**) ROC curve of the Sox10 promoter methylation level in the diagnosis of HD. (**b**) ROC curve of the Sox10 promoter methylation level in the diagnosis of IND. The AUC of *Sox10* methylation in the diagnosis of IND was 0.94 (95% CI, 0.874--1.000, *P* = 0.000). At the cutoff value of 85%, the sensitivity is 90.6%, the specificity is 95.0%, the NPV is 90.99%, and PPV is 94.77%. (**c**) ROC curve of the Sox10 promoter methylation level in the differentiation of IND from HD. The optimal cutoff value of 65% was instructive for IND, with a sensitivity of 56.3%, a specificity of 100%, and a PPV of 100%. Although both sensitivity and accuracy were not satisfactory, the 100% specificity and PPV indicated that when blood *Sox10* promoter methylation was lower than 65%, IND was more likely than HD. CI, confidence interval; HD, Hirschsprung disease; IND, intestinal neuronal dysplasia; NPV, negative predictive value; PPV, positive predictive value; ROC, receiver operating characteristic.](ct9-10-e00093-g006){#F6}

The performance of blood *Sox10* promoter methylation at the 32nd locus in the diagnosis of IND was also evaluated. The AUC of *Sox10* methylation in the diagnosis of IND was 0.94 (95% CI, 0.874--1.000, *P* = 0.000; Figure [6](#F6){ref-type="fig"}b). The cutoff value for IND was determined to be 85%, with a sensitivity of 90.6%, a specificity of 95.0%, and an accuracy of 92.5%, and resulted in an negative predictive value of 90.99% and in a PPV of 94.77%.

Although IND could be diagnosed at a cutoff of 85%, this was not sufficient to distinguish IND from HD because of the high degree of overlap between the symptoms and signs and Sox10 promoter methylation levels. To better distinguish between these 2 conditions, we calculated the AUC of the combined ROC curve, which demonstrated that the AUC for *Sox10* promoter methylation in the diagnosis of IND was 0.835 (95% CI, 0.739--0.931; *P* = 0.000; Figure [6](#F6){ref-type="fig"}c). The optimal cutoff value was determined to be 65% for IND, with a sensitivity of 56.3%, a specificity of 100%, and a PPV of 100%. Although both sensitivity and accuracy were not satisfactory, the 100% specificity and PPV indicated that when blood *Sox10* promoter methylation was lower than 65%, IND was more likely than HD.

DISCUSSION {#s4}
==========

Diagnosis of IND is still a challenge because of the high degree of overlap with HD in terms of symptoms and signs. To date, several standards for IND diagnosis have been proposed, and the identification of giant ganglia has been considered to be critical ([@R23]). To visualize the giant ganglia, many neuronal and muscular markers have been developed, such as the S-100 protein for Schwann cells, CD56 for the size of enteric ganglia ([@R11]), and Bcl-2 for immature neurons ([@R24]). In the present study, *Sox10* was also shown to be a potential indicator. Immunohistochemical staining demonstrated that glial cells were highly proliferative in patients with IND but not in patients with HD. The expression level of *Sox10* was correlated with the number of glial cells. Similar results were reported by Bondurand et al. and Young et al., who argued that *Sox10* is mainly expressed in glial cells of the peripheral nervous system but is silenced in neurons ([@R25],[@R26]). *Sox10* was proposed to play a role in cell fate specification and glial cell differentiation ([@R21],[@R27],[@R28]). It can inhibit neuronal differentiation and must be downregulated during neuronal specification ([@R29],[@R30]). Consistently, *Sox10* was mainly expressed in immature ganglion and mature glial cells and could serve as a biomarker for the identification of giant ganglia in IND.

In recent years, DNA methylation has been reported to be critical for ENS development, playing important roles in the proliferation, migration, and differentiation of neural crest stem cells. In this context, the importance of *Sox10* gene promoter methylation has been demonstrated ([@R14]). Hu et al. ([@R14]) have reported that the methylation of the *Sox*10 promoter by DNMT3B is required for the cessation of neural crest migration. The upregulation of *Sox10* can also induce the demethylation of other neural crest genes, such as *Snail2* and *FoxD3*, leading to their concomitant upregulation ([@R14]). Although the role of *Sox*10 methylation in the development of ENS has been verified, whether it can be used in the diagnosis of ENS anomalies remains unclear. Therefore, we applied a noninvasive genetic method based on the evaluation of the peripheral blood for the diagnosis of ENS anomalies. The results demonstrated that in the peripheral blood, the level of *Sox10* promoter 32nd locus methylation was negatively correlated with *Sox10* expression in the colon. Hence, we concluded that the 32nd locus of the *Sox10* promoter contributed to the regulation of the number of intestinal glial cells and to the maturation of enteric neurons. Thus, *Sox10* DNA methylation could be related to the expression of this gene in response to external environmental stimuli and to the development and maturation of synapses ([@R31]). Based on the present results, *Sox10* methylation at the 32nd locus in the peripheral blood could be used as a diagnostic marker for IND. To further verify this possibility, we evaluated the diagnostic efficiency of this analysis. We found that the level of methylation at the 32nd locus of the *Sox10* promoter was higher in controls than in HD and IND specimens. At a cutoff value of either 85% or 95%, the accuracy of the blood promoter methylation level in HD diagnosis was barely satisfactory because of low specificity or sensitivity. However, this parameter proved effective in IND diagnosis. Because in patients with IND, the blood level of *Sox10* promoter methylation was significantly lower than in control children, and there was little overlap between the 2 groups, the diagnostic efficiency was evaluated in patients with IND. The results showed that at a cutoff value of 85%, the blood level of *Sox10* promoter methylation at the 32nd locus displayed a 90.6% sensitivity and a 95.0% specificity, resulting in high diagnostic accuracy. Therefore, the blood level of *Sox10* promoter methylation may represent a suitable alternative to the invasive examination of colon specimens, also avoiding the need of experienced pathologists. However, because of the overlap of symptoms, signs, and the *Sox10* promoter methylation level between IND and HD, an 85% cutoff was not sufficient to distinguish IND from HD. Therefore, we calculated the AUC of the combined IND and HD ROC curve. The result of this analysis was that when the cutoff value was less than 65%, IND was more likely than HD because the specificity and PPV were both 100%. Notably, this means that when *Sox10* promoter methylation in the blood is between 65% and 85%, additional criteria are required to distinguish IND from HD.

Although the determination of *Sox10* promoter methylation in the blood implies enormous advantages over the conventional approach to IND diagnosis, this method also has a few intrinsic drawbacks. First, although it may allow for IND diagnosis, it provides no clues on the extent of the lesion, and colon specimens are still necessary to obtain this information. Second, because of the low incidence of IND, large numbers of samples are difficult to achieve in the short term. Larger studies must therefore be performed to further explore the efficacy of blood DNA testing as a noninvasive method for IND diagnosis. Finally, the level of DNA methylation in the blood can be influenced by many factors, such as viral infection, pesticide exposure, radiation, and age ([@R32]--[@R35]). On the other hand, as long as these confounding factors are properly controlled, we believe that in most cases, blood DNA methylation can be a suitable method for IND diagnosis.

In summary, blood *Sox10* promoter methylation can be used as a noninvasive and efficient diagnostic method for IND, particularly when the extent of Sox10 promoter methylation is lower than 65%.
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